IA
BCRX icon

IFP Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

IFP Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.4K Buy
3,243
+3,119
+2,515% +$28.2K ﹤0.01% 2670
2026
Q1 		$1.18K Hold
124
– – ﹤0.01% 4153
2025
Q4 		$967 Sell
124
-565
-82% -$4.08K ﹤0.01% 4082
2025
Q3 		$5.23K Sell
689
-39
-5% -$325 ﹤0.01% 3223
2025
Q2 		$6.52K Buy
728
+675
+1,274% +$6.29K ﹤0.01% 3182
2025
Q1 		$398 Hold
53
– – ﹤0.01% 3511
2024
Q4 		$399 Buy
+53
New +$402 ﹤0.01% 3480
2023
Q4 		– Sell
-25
Closed -$177 – 3076
2023
Q3 		$177 Hold
25
– – ﹤0.01% 3204
2023
Q2 		$176 Sell
25
-1
-4% -$8 ﹤0.01% 3325
2023
Q1 		$162 Sell
26
-5,517
-100% -$53.1K ﹤0.01% 3287
2022
Q4 		$35K Sell
5,543
-208
-4% -$2.59K ﹤0.01% 2478
2022
Q3 		$36K Hold
5,751
– – ﹤0.01% 2629
2022
Q2 		$36K Hold
5,751
– – ﹤0.01% 2393
2022
Q1 		$36K Buy
5,751
+5,673
+7,273% +$91K ﹤0.01% 2393
2021
Q4 		$1K Sell
78
-460
-86% -$6.09K ﹤0.01% 2940
2021
Q3 		$7K Sell
538
-8,284
-94% -$131K ﹤0.01% 2402
2021
Q2 		$140K Buy
8,822
+2,723
+45% +$37K ﹤0.01% 1077
2021
Q1 		$63K Sell
6,099
-1,196
-16% -$12.3K ﹤0.01% 1357
2020
Q4 		$55K Buy
7,295
+5,095
+232% +$26.3K ﹤0.01% 1401
2020
Q3 		$7K Buy
+2,200
New +$9.43K ﹤0.01% 2024
2017
Q4 		– Sell
-1,000
Closed -$5K – 3813
2017
Q3 		$5K Hold
1,000
– – ﹤0.01% 3364
2017
Q2 		$6K Hold
1,000
– – ﹤0.01% 3281
2017
Q1 		$8K Hold
1,000
– – ﹤0.01% 3029
2016
Q4 		$6K Hold
1,000
– – ﹤0.01% 3177
2016
Q3 		$4K Hold
1,000
– – ﹤0.01% 3303
2016
Q2 		$3K Buy
+1,000
New +$3.1K ﹤0.01% 3322
2016
Q1 		– Sell
-1,000
Closed -$10K – 2442
2015
Q4 		$10K Buy
+1,000
New +$9.94K ﹤0.01% 2570

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

IFP Advisors's BCRX Position: Q2 2026 in Review

IFP Advisors increased its BioCryst Pharmaceuticals (BCRX) stake by 2,515% in Q2 2026, buying an estimated $28.2K and bringing the position to 3,243 shares worth $32.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2670.

IFP Advisors first reported a position in BCRX in Q4 2015 and has held it in 27 quarters since. The position peaked at $140K in Q2 2021. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • IFP Advisors held 3,243 shares of BioCryst Pharmaceuticals worth $32.4K as of Q2 2026.
  • IFP Advisors bought 3,119 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $28.2K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #2670 holding.
  • IFP Advisors first reported a position in BioCryst Pharmaceuticals in Q4 2015 and has held it in 27 quarters since.
  • IFP Advisors's BioCryst Pharmaceuticals position peaked at $140K in Q2 2021.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.